Daily Stock Analysis, GALT, Galectin Therapeutics Inc, priceseries

Galectin Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
4.65
Close
4.78
High
4.89
Low
4.40
Previous Close
4.62
Daily Price Gain
0.16
YTD High
6.06
YTD High Date
Feb 21, 2019
YTD Low
3.44
YTD Low Date
Jan 2, 2019
YTD Price Change
0.92
YTD Gain
23.83%
52 Week High
9.49
52 Week High Date
Jun 18, 2018
52 Week Low
3.10
52 Week Low Date
May 8, 2018
52 Week Price Change
1.37
52 Week Gain
40.18%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 9. 2017
1.25
Mar 2. 2017
1.66
14 Trading Days
32.98%
Link
LONG
Apr 5. 2017
2.15
Apr 28. 2017
3.12
16 Trading Days
44.98%
Link
LONG
Sep 20. 2017
1.75
Oct 16. 2017
2.46
18 Trading Days
40.47%
Link
LONG
Dec 22. 2017
2.58
Jan 22. 2018
5.31
18 Trading Days
105.99%
Link
LONG
May 25. 2018
4.20
Jun 20. 2018
7.36
17 Trading Days
75.12%
Link
LONG
Aug 28. 2018
4.57
Sep 6. 2018
5.28
6 Trading Days
15.55%
Link
LONG
Sep 17. 2018
5.74
Sep 25. 2018
6.04
6 Trading Days
5.18%
Link
LONG
Nov 1. 2018
4.75
Nov 6. 2018
5.10
3 Trading Days
7.37%
Link
LONG
Jan 4. 2019
4.05
Jan 23. 2019
4.58
12 Trading Days
13.18%
Link
LONG
Feb 14. 2019
4.97
Feb 26. 2019
5.23
7 Trading Days
5.28%
Link
Company Information
Stock Symbol
GALT
Exchange
NasdaqCM
Company URL
http://www.galectintherapeutics.com
Company Phone
678-620-3186
CEO
Peter G. Traber
Headquarters
Georgia
Business Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA 30071
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001133416
About

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.

Description

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.